UroGen Pharma Ltd.
URGN
$47.11
$0.801.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 42.18% | 34.68% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 42.18% | 34.68% | |||
| Cost of Revenue | 58.78% | 25.84% | |||
| Gross Profit | 40.72% | 35.52% | |||
| SG&A Expenses | -5.92% | 30.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.58% | 25.06% | |||
| Operating Income | 100.55% | -6.01% | |||
| Income Before Tax | 69.23% | -6.41% | |||
| Income Tax Expenses | 217.96% | -1,635.27% | |||
| Earnings from Continuing Operations | 39.12% | 10.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.12% | 10.58% | |||
| EBIT | 100.55% | -6.01% | |||
| EBITDA | 100.94% | -6.03% | |||
| EPS Basic | 39.36% | 12.27% | |||
| Normalized Basic EPS | 69.35% | -4.38% | |||
| EPS Diluted | 39.36% | 12.27% | |||
| Normalized Diluted EPS | 69.35% | -4.38% | |||
| Average Basic Shares Outstanding | 0.39% | 1.93% | |||
| Average Diluted Shares Outstanding | 0.39% | 1.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||